Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, UK
Imaging technologies have become a key aspect of the pharmaceutical research & development process to understand the complexity of biological events happening within tissue. The growth of spatial-omics is giving access to transcriptomic, proteomic and metabolomic data in a single tissue slice.
At AstraZeneca, we’re integrating those data with gold standard histological methods to generate a holistic understanding of drug action using Mass Spectrometry Imaging (MSI) and Imaging Mass Cytometry (IMC). The integration of both technologies is playing a pivotal role in modern drug development by providing Pharmacokinetics (PK), Pharmacodynamics (PD), safety and target engagement (TE) information, crucial for decision making.
This presentation will showcase< different examples of application dealing with cancer research to describe how MSI & IMC are in the centre of the development of spatial biology when integrated with other imaging and omics approaches. Thus, differences in tissue beyond pathology can be detected informing about the tumour biology and metabolism in greater details and provide the true measurement of heterogeneity and comparative response to drug in tissues.
LIH – Edison
Room: Curie-Pasteur (3rd floor)
1B, rue Thomas Edison
LECTURE: 10:00am – 11:00am
Please note that registration is mandatory by sending an email to firstname.lastname@example.org
Read more about the “Data Protection Notice: processing of personal data in the scope of events’ management”.